Aziz Ahmed Ali, Omar Nosheen, Shah Rehan, Aziz Muhammad Ali, Ali Ijlal Akbar
Internal Medicine, Capital Health Regional Medical Center, Trenton, USA.
Anatomy, University of Health Sciences, Lahore, PAK.
Cureus. 2025 Jul 16;17(7):e88107. doi: 10.7759/cureus.88107. eCollection 2025 Jul.
Transarterial radioembolization (TARE) is a relatively new treatment option available for unresectable hepatocellular carcinoma (HCC). TARE therapy involves the delivery of radiation directly to the tumor to cause tumor necrosis. Yttrium-90 (Y90) is commonly used as a source of radioembolization in TARE. TARE is very well tolerated and has a low rate of complications. Main complications of TARE for HCC include postembolization syndrome and radiation-induced injury to nearby organs such as the liver, gallbladder, and stomach, causing hepatitis, cholecystitis, or gastric ulceration. A side effect not previously described in TARE literature is portal venous gas after TARE therapy. We present the first ever reported case of portal and variceal venous gas in a 77-year-old male patient who had unresectable HCC and had previously failed chemotherapy. He underwent Y90 TARE for HCC. Following TARE, he presented with right upper quadrant abdominal pain, and imaging showed portal and variceal venous gas. He was treated with antibiotics, with resolution of symptoms and improvement in portal and variceal venous gas on repeat imaging.
经动脉放射性栓塞术(TARE)是一种可用于不可切除肝细胞癌(HCC)的相对较新的治疗选择。TARE疗法包括将辐射直接传递到肿瘤以导致肿瘤坏死。钇-90(Y90)通常用作TARE中的放射性栓塞源。TARE耐受性良好,并发症发生率低。TARE治疗HCC的主要并发症包括栓塞后综合征以及对附近器官如肝脏、胆囊和胃的辐射诱导损伤,导致肝炎、胆囊炎或胃溃疡。TARE文献中以前未描述过的一种副作用是TARE治疗后出现门静脉气体。我们报告了首例有门静脉和静脉曲张气体的病例,患者为一名77岁男性,患有不可切除的HCC且先前化疗失败。他接受了针对HCC的Y90 TARE治疗。TARE治疗后,他出现右上腹疼痛,影像学检查显示门静脉和静脉曲张气体。他接受了抗生素治疗,症状缓解,重复影像学检查显示门静脉和静脉曲张气体有所改善。